We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) (STAREE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02099123
Recruitment Status : Recruiting
First Posted : March 28, 2014
Last Update Posted : September 14, 2022
National Health and Medical Research Council, Australia
National Heart Foundation, Australia
Information provided by (Responsible Party):
Sophia Zoungas, Monash University

Brief Summary:
The STAREE study will examine whether treatment with statin (atorvastatin 40mg) compared with placebo will prolong overall survival or disability free survival amongst healthy elderly people (≥70 years).

Condition or disease Intervention/treatment Phase
Independent Living Disability Free Survival Elderly Healthy Drug: Atorvastatin Drug: Placebo (for Atorvastatin) Phase 4

Detailed Description:

Statin therapy has been shown to reduce the risk of vascular events in younger individuals with manifest atherosclerotic disease or at high risk of vascular events. However, data derived from meta-analyses of existing trials suggests that the efficacy of statins may decline sharply amongst those over 70-75 years of age. Insufficient patients of this age group have been included in major trials to be certain of the benefit. Within this age group part of the benefit of statin therapy may be offset by adverse effects including myopathy, development of diabetes, cancer and cognitive impairment, all of which are more prevalent in the elderly in any event.

The use of statins in the over 70 age group raises fundamental questions about the purpose of preventive drug therapy in this age group. When a preventive agent is used in the context of competing mortality, polypharmacy and a higher incidence of adverse effects its use should be justified by an improvement in quality of life or some other composite measure that demonstrates that the benefit outweighs other factors.

STAREE will determine whether taking daily statin therapy (40 mg atorvastatin) will extend the length of a disability-free life, determined from survival outside permanent residential care, in healthy participants aged 70 years and above.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Study of STAtins for Reducing Events in the Elderly (STAREE)
Study Start Date : July 2015
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Atorvastatin
40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
Drug: Atorvastatin
Atorvastatin 20 mg tablet
Other Names:
  • Lipitor, , , Cadivast, Caduet, Lorstat, Torvastat, Trovas
  • Atorachol
  • Cadatin

Placebo Comparator: Placebo
Placebo (2 x 20 mg placebo) taken orally once daily
Drug: Placebo (for Atorvastatin)
Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
Other Name: no other names

Primary Outcome Measures :
  1. (i) to death or development of dementia (as measured by cognitive function tests) or development of disability (as measured by the KATZ ADL test), or (ii) to a major fatal or non-fatal cardiovascular event. [ Time Frame: Time from randomisation to a primary endpoint ]
    The primary endpoint is either the time from randomisation (i) to death or development of dementia (as measured by cognitive function tests) or development of disability (as measured by the KATZ ADL33 test), or (ii) to a major fatal or non-fatal cardiovascular event.

Secondary Outcome Measures :
  1. Cardiovascular death [ Time Frame: From date of randomisation until the date of a death to a cardiovascular cause ]
    Fatal cardiovascular events

  2. Fatal and Non-fatal Mycocardial infarction [ Time Frame: From date of randomisation until the date of of diagnosis of a myocardial infarction ]
    Fatal and non-fatal

  3. Hospitalisations [ Time Frame: From date of randomisation until the date of hospitalisation ]
    Hospitalisation reasons and length of stay

  4. New onset diabetes [ Time Frame: From date of randomisation until the date of diagnosis of diabetes ]
    New diagnosis of diabetes

  5. Fatal and Non-fatal Cancer [ Time Frame: From date of randomisation until the date of death due to cancer or date of first date of first cancer event ]
    Fatal and Non-fatal Cancer (excluding non-melanoma skin cancer)

  6. Cognitive decline [ Time Frame: From date of randomisation until the date of a change in the 3Ms resulting in a diagnosis of cognitive decline ]
    Cognitive decline as assessed using the 3MS excluding depression

  7. Quality of life measured by the Short Form Health Survey (SF-36) [ Time Frame: Assessed annually ]
    Quality of life (measured by the Short Form Health Survey (SF-36) administered at every second year of follow-up).

  8. Cost-effectiveness of statin [ Time Frame: Up to 60 months ]
    Cost-effectiveness of statin

  9. Fatal and Non-fatal Stroke [ Time Frame: From date of randomisation until the date of a diagnoses stroke ]
    Fatal and Non-fatal Stroke can be a) haemorrhagic or b) thromboembolic

  10. Approved need for permanent residential care [ Time Frame: Approved need for residential care as reported by the Aged care assessment team ]
    ACAS report

  11. All cause dementia [ Time Frame: All cause dementia as assessed by cognitive tests ]
    All-cause dementia (COWAT, Stroop test, Trail Making Test, HVLT-R, SDMT, ADAS-Cog, Lurian overlapping figures)

  12. Frailty/Disability [ Time Frame: As assesed using the KATZ-ADL ]
    KATZ-ADL administered every 6 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women aged ≥70 years living independently in the community
  • Willing and able to provide informed consent and accept the study requirements (Note: competent physical ability to participate in the trial is assessed using the KATZ ADL questionnaire)

Exclusion Criteria:

A history of cardiovascular disease (defined as myocardial infarction, stroke, peripheral vascular disease, angina, transient ischaemic attack, coronary artery angioplasty and/or stenting, coronary artery bypass grafting or heart failure),

  • A history of dementia or a 3MS score <78 on screening,
  • A history of diabetes,
  • Total cholesterol >7.5 mmol/L,
  • Moderate or severe chronic kidney disease (persistent proteinuria (Urine albumin:creatinine ratio >30mg/mmol or Urine protein:creatinine ratios >45 mg/mmol)45 and/or eGFR <45ml/min/1.73m2),
  • Moderate or severe liver disease (persistent elevations of transaminases of more than 3 times the upper limit of the normal laboratory reference range),
  • Serious inter-current illness likely to cause death within the next 5 years such as terminal cancer or obstructive airways disease,
  • Current participation in a clinical trial (Note: If yes, this is only an exclusion if other trial involves taking a drug or another intervention)
  • Absolute contraindication to statin therapy,
  • Current use of statin therapy or other lipid lowering therapy for primary prevention and unwilling to stop therapy,
  • Current long term or permanent use of the following cytochrome P450 (CYP) 3A4 inhibitors : Amiodarone, Boceprevir, Cimetidine, Cyclosporin, Danazol, Fosamprenavir, Indinavir, Lopinavir + Ritonavir, Erythromycin, Fluconazole, Itraconazole, Ketoconazole.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02099123

Layout table for location contacts
Contact: Sophia Zoungas, MBBS, FRACP +61 1800 770 664 staree@monash.edu

Layout table for location information
Australia, Tasmania
Tasmania Recruiting
Hobart, Tasmania, Australia
Contact: Mark Nelson         
Australia, Victoria
Victoria Recruiting
Melbourne, Victoria, Australia
Australia, Western Australia
South Australia Recruiting
Adelaide, Western Australia, Australia
Contact: Sophia Zoungas         
Queensland Recruiting
Brisbane, Australia
Contact: Sophia Zoungas         
New South Wales Recruiting
Newcastle, Australia
Contact: Andrew Boyle         
Western Australia Recruiting
Perth, Australia
Contact: Christopher Reid         
Sponsors and Collaborators
Monash University
National Health and Medical Research Council, Australia
National Heart Foundation, Australia
Layout table for investigator information
Principal Investigator: Sophia Zoungas, MBBS, FRACP Monash University
Layout table for additonal information
Responsible Party: Sophia Zoungas, Professor Sophia Zoungas, Monash University
ClinicalTrials.gov Identifier: NCT02099123    
Other Study ID Numbers: NHMRC 1068146
First Posted: March 28, 2014    Key Record Dates
Last Update Posted: September 14, 2022
Last Verified: September 2022
Keywords provided by Sophia Zoungas, Monash University:
Functional Disability
Cardiovascular Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors